« Return to News | Clinical Intelligence

Bert Spilker's Pharma Principles of The Week

Friday, January 12, 2007 03:08 PM

Posted by: Bert Spilker

  • Exercise great caution in hiring academic or government employees into the industry as leaders, as you may have to spend years of “on the job training” to have them reach the state that many industrial managers are at today.  Many academic and government managers or scientists never adapt adequately in industry, and a company takes a great risk when it hires these people.
  • Are the company’s managers mainly living in the past, present or future?  How many are in the present and keeping an eye on the future while planning how to get there?  Where are you living?
  • Professional talks and presentations are not like mystery novels where you build to a glorious climax and conclusion. Share the conclusions up front with your audience.  Tell them what you will tell them, then tell them, and then tell them what you told them.

Bert Spilker, PhD, MD is an independent consultant who was most recently the Senior Vice President of Scientific and Regulatory Affairs for PhRMA. He is the founder of Bert Spilker & Associates (BS&A).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.